intestine ͉ tumorigenesis ͉ cell fusion ͉ tissue regeneration
T he use of adult stem cells for therapeutic treatment of human disease has great potential. Recently, adult stem cells were successfully used for gene therapy in a mouse model of Type 1 tyrosinema (1) and demonstrated to accelerate wound healing in a human burn patient (2) . Although the biological significance and potential clinical applications of the incorporation of bone marrow-derived cells (BMDCs) are unquestionably important (2) (3) (4) (5) , the underlying mechanism of cell incorporation into other organs remains unclear. The mechanism of cellular fusion of BMDCs with host cells in organs such as the liver has been elegantly illustrated by using serially transplanted cells and extensive karyotyping of engrafted cells (6, 7) . Other studies, however, suggest that BMDCs incorporate into organs through mechanisms whereby the transplanted cells transdifferentiate into tissue-specific stem cells (8) (9) (10) . The means of BMDC incorporation in the intestine, however, have not been fully defined. Recent reports illustrate that BMDCs incorporate into the pericryptal fibroblast region of the small intestine (11) and contribute to the intestinal epithelium of human gendermismatched bone marrow transplants (12) . However, neither of these observations has been attributed to a cellular fusion mechanism. To understand the role of BMDC contribution in the progression of disease or the regeneration of damaged tissue, the underlying mechanism and cellular participants must be identified.
Although it may be possible that BMDCs participate in intestinal epithelial regeneration or repair through a variety of different mechanisms, it has been hypothesized that circulating BMDCs could fuse with transformed intestinal epithelium to confer phenotypic and genotypic diversity to the tumor (13) and participate in tumorigenesis (14) (15) (16) . It is intriguing to hypothesize that these rare fusion events may lead to a cell type that possesses greater metastatic characteristics. Currently, in vitro studies support this hypothesis (17) , although in vivo occurrences of this phenomenon have been difficult to prove. In this study, we show that transplanted BMDCs can incorporate into the intestinal epithelium of gamma-irradiated mice through a fusion mechanism and provide evidence that the intestinal stem cell is the fusion partner. Finally, we provide in vivo evidence that strongly supports the hypothesis that fusion between circulating hematopoietic cells and transformed intestinal epithelium is involved in intestinal tumorigenesis.
Results and Discussion
To determine the fate of BMDCs in intestinal epithelium, we transplanted whole bone marrow or hematopoietic stem cells (HSCs) from female EGFP-or ␤-gal-expressing mice into lethally irradiated male recipients. As early as 2 weeks and for as long as 14 months after transplant, donor-derived cells were detected in both crypt and villus epithelium, and lamina propria of the small intestine at a sustained level ( Fig. 1 A-C) . EGFPand ␤-gal-expressing crypts identified by whole-mount analysis were confirmed with antibody staining of intestinal tissue sections. Moreover, donor-derived cells were detected readily in the pericryptal mesenchyme as reported in ref. 11 . Similar results were observed after transplantation of highly purified HSCs ( Fig. 1 D-F) . The architecture of crypt-villus units containing EGFP-expressing cells was morphologically indistinguishable from regions devoid of epithelial-derived donor cells. EGFPexpressing cells were present in discontinuous regions throughout the epithelium, a finding that is likely due to variegation of EGFP transgene expression that is also observed within the intestinal epithelium of the transgenic donor mouse (Fig. 7 , which is published as supporting information on the PNAS web site). In contrast, ␤-gal is ubiquitously expressed in the intestinal epithelium of reverse orientation splice acceptor 26 (ROSA26) mice (18) , which prompted us to use it as a marker to determine the efficiency of donor cell incorporation. For this calculation, we counted the number of donor-derived intestinal crypts in whole-mount-prepared intestines from transplanted mice (Fig.  1B) . Although donor-derived intestinal crypts were present throughout the length of the intestine, they were most frequent in the distal region of the small intestine and represented 0.25 Ϯ 0.05% of total crypts (n ϭ 4 animals). The level of donor cell incorporation into the intestine was similar for both whole bone marrow-and HSC-transplanted intestines, implicating an HSC or its progeny as the donor cell responsible. In these mice, chimerism in the peripheral blood ranged from 80% to 90%. The percentage of donor-derived cells in the intestine is consistent with levels reported in other tissues (19) .
To determine whether cell fusion is the mechanism that facilitates BMDC integration, we assayed for presence of the Y chromosome in donor-derived cells in the intestines of transplanted male mice (Fig. 2 A-C) . Colocalization of donor-derived EGFP expression and recipient-specific Y chromosome labeling within the same cell indicated that these two cell populations had undergone fusion (Fig. 2 A-C ). An average of 51% of the donor-derived cells were positive for both markers in a total of 200 epithelial nuclei analyzed from six mice. Because the villus epithelial compartment is anatomically distinct from the hematopoietic cells that reside within the lamina propria, it is unlikely that cells positive for both the Y chromosome and EGFP represent contaminating lymphocytes or macrophages. This distinction was confirmed by using antibodies to the panhematopoietic marker CD45 (Fig. 8 , which is published as supporting information on the PNAS web site). WT male intestinal sections probed with whole Y chromosome paint produced a detectable signal in Ϸ85% of cells (Fig. 9 , which is published as supporting information on the PNAS web site). By using the percentage of detectable Y chromosomes as a correction factor, Ϸ60% of donor-derived epithelial cells were positive for both donor and recipient cell markers.
A second independent approach for examining fusion in the intestine supported these initial observations. In ␤-galexpressing recipient male mice transplanted with female EGFPexpressing BMDCs, both ␤-gal and EGFP were detected in the same epithelial cell by using confocal microscopy ( Fig. 2 D-F) . We were unable to identify intestinal regions containing cells expressing EGFP but not ␤-gal. This finding suggests that using the Y chromosome approach as a host-specific marker may underestimate the extent of cellular fusion.
Importantly, fusion between BMDCs and intestinal epithelial cells resulted in a morphologically normal epithelial population. To address the fate of the initial fusion product, we surveyed hematopoietic gene expression within the donor-derived cells in the intestinal epithelium. Expression of CD45, c-kit, or Sca-1 was present in cells residing within the lamina propria but was absent from all intestinal epithelial cells (Fig. 8) . These results suggest that the nuclei of the fused cells have been reprogrammed and no longer express these hematopoietic markers. We found BMDC-expressing markers for all four principal intestinal epithelial lineages for up to 6-14 months after transplantation. Donor-derived absorptive enterocytes were identified by double labeling of intestinal sections with antibodies to EGFP and to cytokeratin (Fig. 3 B-D) and the epithelial differentiation marker Fatty acid binding protein (Fabp; data not shown). There was no apparent difference in enterocytic cytokeratin or Fabp expression between EGFP-positive or WT cells, indicating that EGFP-expressing enterocytes possessed normal differentiation profiles. The three secretory lineages also were represented among the donor-derived population. Differentiation of donorderived cells into enteroendocrine cells was demonstrated with antibodies to serotonin (Fig. 3 E-G) . Donor-derived goblet cells were morphologically identified by brightfield detection for EGFP-expressing cells (Fig. 3A, black asterisk) . Moreover, both donor-derived goblet cells and Paneth cells also were identified by lectin staining (data not shown).
The presence of donor-derived cells in all four principal epithelial lineages and even more so, the presence of multiple differentiated epithelial lineages in a single villus, indicate that BMDCs fuse with a multipotent intestinal progenitor or stem cell. The multipotent intestinal stem cell has been shown to give rise to all four principal epithelial lineages (20) . These epithelial cells migrate in a linear fashion out of the monoclonal crypts onto the adjacent villi (21) . Therefore, EGFP-expressing epithelium detected with brightfield methods allows for morphologic identification of mucous-secreting goblet cells interspersed among absorptive enterocytes (Figs. 1C and 3A) and suggests that these cells are clonally derived. Furthermore, long-term detection of EGFP-expressing cells suggests that a long-lived progenitor͞stem cell population propagates the EGFP signal, because the differentiated intestinal epithelium is rapidly renewing and turns over every 3-5 days (22) . Therefore, if the BMDCs fuse with differentiated cells, donor-derived markers would be absent at the later posttransplantation time points. Lineagecommitted progenitor cells are retained in the intestine for Ϸ100 days (23), whereas long-lived progenitors and stem cells reside for longer periods. Although the persistence of donor-derived epithelium in transplanted mice suggests BMDC fusion with a long-lived progenitor or intestinal stem cell, it does not rule out fusion with lineage progenitor cells or even differentiated cells. It is unlikely that donor-derived intestinal cells of various differentiated lineages are derived from continuously occurring direct fusion events, because EGFP-expressing BMDCs failed to incorporate into the intestinal epithelium of nonirradiated mice (data not shown). This observation suggests that local injury is important for BMDC fusion and that this fusion mechanism participates in epithelial regeneration.
Our data suggest that fusion of BMDCs with WT intestinal epithelial cells occurs in the stem cell niche of the small intestine. This observation led us to ask whether transplanted BMDCs have an increased propensity to incorporate into the highly proliferative epithelium of intestinal tumors or whether they act as tumor stem cells, as has been recently reported in gastric carcinoma (16) . Remarkably, we found that EGFPexpressing BMDCs incorporate into tumor intestinal epithelium of mice harboring intestinal adenomas (24) (Min mice) at a higher frequency when compared with WT intestinal epithelium (Fig. 4A) . Although EGFP-expressing cells were observed in the majority of intestinal adenomas screened, we did not detect any ubiquitously EGFP-expressing adenomas. This finding, along with the observation that BMDC transplant did not alter overall polyp number (Fig. 10 , which is published as supporting information on the PNAS web site), suggests that BMDCs are not involved in tumor initiation in the small intestine. Donor-derived tumor epithelium possessed a normal expression pattern of cytokeratin, a widely expressed epithelial marker (Fig. 4 B and C) , but failed to express the intestinal epithelial differentiation marker Fabpl (25); Fig. 4 D and E) . Loss of epithelial differentiation markers suggests that EGFPexpressing tumor epithelium fuse to undifferentiated or stem cell-like tumor cells. Alternatively, integrated donor cells may fail to efficiently express tissue-specific differentiation markers as a response to the tumor environment. Similar to donor-derived epithelium in WT recipients, EGFP-expressing tumor epithelium did not express hematopoietic differentiation markers (data not shown).
To determine whether transplanted BMDCs incorporate into tumor epithelium by cell fusion, we analyzed EGFP-expressing regions of intestinal adenomas for the presence of the hostspecific Y chromosome. Donor-derived cells expressed both EGFP and the Y chromosome, indicating that cell fusion had occurred (Fig. 4 F-H) . Because the transplanted BMDCs contain WT copies of the Apc gene, it is unlikely that these cells could acquire mutations in both alleles and give rise to intestinal adenomas within 2 weeks after transplantation. Our data strongly support the notion that BMDCs fuse with tumor epithelium rather than function as a tumor stem cell as reported in gastric cancer (16) . However, the previous study did not use a dual marker system for detecting donor and recipient populations, but rather relied on the absence of multiple nuclei to exclude fusion. Therefore, it is possible that unrecognized cell fusion also may underlie BMDC incorporation into tumors of the gastric epithelium.
Although our data directly demonstrate that BMDCs fuse with the intestinal epithelium, we cannot rule out additional mechanisms for BMDC incorporation into the intestinal epithelium (26) because the Y chromosome was undetected in up to 40% of donor-derived epithelial cells. However, using the Y chromosome as a host-specific marker leads to underestimation of fusion events, which suggests that alternative mechanisms such as transdifferentiation might be rare.
Importantly, our findings show that BMDCs can fuse with a long-lived progenitor or intestinal stem cell population of gamma-irradiated damaged intestinal epithelium. Fusion of BMDCs with progenitors or stem cells may play an important role in regeneration of damaged tissue. Currently, the role of BMDC fusion with tumor epithelium is less clear. Although it is apparent that incorporation of these cells into intestinal adenomas does not initiate cancer of the small intestine, Min mice do not survive long enough to evaluate the impact of fusion on tumor progression. Although our data do not support the notion that BMDCs act as tumor stem cells, the fusion between BMDCs and tumor cells may be a common but late event in intestinal tumorigenesis. There is precedence for the involvement of BMDCs in tumorigenesis, as demonstrated by the contribution of these cells to tumor vasculature (15) and in initiation of the angiogenic switch that is critical for tumor progression (14) . Further, there is in vitro evidence that fusion between bloodderived cells and tumor cell lines results in a more metastatic cellular product (13) . Thus the in vivo fate of these fusogenic cells is clearly important. Whether this fusion event allows cells to acquire metastatic potential or whether they become genetically unstable remains to be investigated. The observation that BMDCs can fuse with tumor epithelium is an important finding, and further examination of this event will enhance our understanding of the biology of tumorigenesis and may provide a novel strategy for the development of anticancer therapies.
Materials and Methods
Bone Marrow Transplantation. BMDCs were harvested from 5-to 12-week-old female donor mice harboring ␤-gal (ROSA26; ref. 18) or EGFP transgenes (27) by using standard procedures (28) . Harvested bone marrow was filtered to obtain a single-cell suspension and resuspended in modified Hank's balanced salt solution (HBSS). HSCs were isolated as described in ref. 29 . An aliquot was diluted in Turk's reagent (Merck, Darmstadt, Germany) to perform a cell count. To prepare recipient mice for transplantation, 8-week-old recipient male C57BL͞6 mice or 5-week-old recipient male Min mice (The Jackson Laboratory) were enterally administered acidified water (pH 2.2) for 1 week before whole-body gamma irradiation (12 Gy) in two equal doses, 4 hours apart. The early intestinal epithelial response to 12 Gy is crypt cell apoptotic death; however, clonogenic regeneration of the crypt is observed over the first 4 days after irradiation, and complete healing of the epithelium is apparent by 7 days after irradiation (30) . A total of 5 ϫ 10 6 unfractionated donor bone marrow cells (or 500 HSCs) were then injected into the retro-orbital plexus of the recipient mouse. All recipient mice were administered antibiotic drinking water (neomycin sulfate at 1.1 g͞liter and polymixin B sulfate at 167 mg͞liter) for 1 month after transplantation to reduce infection. Nonirradiated control recipient mice were transplanted once daily with 2 ϫ 10 7 bone marrow cells retro-orbitally for 5 sequential days. Mice were analyzed at 5 weeks after transplantation. All procedures were performed in accordance to the Oregon Health & Science University Animal Care and Use Committee.
Analysis of Transplanted Intestine. BMDC-transplanted mice were analyzed at various times between 2 weeks and 14 months after transplant. Whole-mount analysis was conducted as described in ref. 31 , except that intestines were fixed with 4% paraformaldehyde and visualized with fluorescence (EGFP bandpass filter 470͞40 nm) for EGFP-incorporated intestines or with X-Gal and light microscopy for ROSA26-incorporated intestines, and images were captured digitally. The number of donor-derived intestinal crypts were quantified in mice transplanted with ROSA26 bone marrow by counting the number of X-Galpositive crypts in the distal third of the small intestine and was reported as LacZ-positive crypts per cm 2 . Standard error of the mean and significance were calculated.
After gross analysis of the intestine, frozen blocks were prepared and sectioned as described in ref. 31 . Five-micrometerthick sections were analyzed for EGFP-expressing cells by using polyclonal antibodies (1:250; Molecular Probes) and fluorescent secondary antibodies [indocarbo-cyanine (Cy3)-labeled donkey anti-rabbit antibody; 1:500; Jackson ImmunoResearch] or for brightfield detection by using biotin-avidin secondary antibodies and visualization with 3-3Ј-diaminobenzidine (DAB) according to the manufacturer's guidelines (Vector Laboratories). EGFPexpressing cells were double-labeled with antibodies to hematopoietic lineage markers (CD45 and c-kit; eBioscience, San Diego) or intestinal epithelial-specific markers (Fabp, a kind gift from J. I. Gordon, Washington University School of Medicine, St. Louis; cytokeratin, Research Diagnostics, Flanders, NJ; and 5␣-HT, lysozyme, Peninsula Laboratories). Sections were examined by using a Leica DMR microscope and standard epifluorescence filters for FITC (470͞40) and Cy3 (535͞50). Digital images were captured.
Analysis of Cell Fusion. Y chromosome FISH was performed on EGFP-transplanted intestinal paraffin sections. EGFPexpressing cells first were identified by using antigen retrieval (5 mM sodium citrate buffer, pH 6.0), polyclonal EGFP antibodies, and brightfield development with DAB (Vector Laboratories). Adjacent serial sections then were stained as before with EGFP antibodies but with light DAB detection to facilitate subsequent detection of the Y chromosome on the same tissue section. FISH was subsequently performed as previously reported by using Cy3-conjugated Y chromosome paint (Cambio, Cambridge, U.K.) followed by incubation with 2Ј-(4-hydroxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5Ј-bi(1H-benzimidazole) trihydrochloride (Hoechst 33258; 0.1 g͞ml in PBS for 10 min). The presence of the Y chromosome was localized to the nucleus by using overlay of Hoechst-stained and Cy3-stained digital images and confirmed by confocal microscopy. Tissue sections of EGFPexpressing female or male mice were used as controls.
Analysis of EGFP-transplanted ROSA26 intestines was performed as described above. Intestinal sections of transplanted mice were stained with antibodies for ␤-gal (1:100; Eppendorf). Secondary antibodies conjugated to Cy5 were used for ␤-gal detection because the excitation spectrum for Cy5 (590-650 nm) is spectrally separate from the fluorescence emission of EGFP (450-570 nm). Regions coexpressing EGFP and ␤-gal were identified by using a MRC-1024 confocal laser scanning imaging system (Bio-Rad).
